2025. A Repurposed Duo: Empagliflozin-Metformin Triggers a Metabolic Crisis in Cervical Cancer by Disrupting the Acyl-CoA/CoA Ratio via Dual Inhibition of PPAT and CPT1A. Journal of Cancer Research Updates. 14, (Dec. 2025), 247–265. DOI:https://doi.org/10.30683/1929-2279.2025.14.26.